Compare OBT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | ENTA |
|---|---|---|
| Founded | 1892 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.6M | 486.3M |
| IPO Year | 2021 | 2012 |
| Metric | OBT | ENTA |
|---|---|---|
| Price | $33.40 | $14.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $36.00 | $20.40 |
| AVG Volume (30 Days) | 70.7K | ★ 171.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $14.27 | $1.94 |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $13.87 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $20.97 | $4.09 |
| 52 Week High | $37.99 | $17.15 |
| Indicator | OBT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 56.64 |
| Support Level | $23.17 | $13.39 |
| Resistance Level | $37.99 | $15.45 |
| Average True Range (ATR) | 1.27 | 0.83 |
| MACD | -0.38 | 0.08 |
| Stochastic Oscillator | 13.08 | 53.75 |
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.